Juan Carlos Martnez-Castrillo

List of Publications by Citations

Source:

https://exaly.com/author-pdf/1314358/juan-carlos-martinez-castrillo-publications-by-citations.pdf **Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140 5,491 37 71 g-index

163 6,889 4.4 4.99 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
140	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology, The</i> , 2019 , 18, 1091-1102	24.1	562
139	Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. <i>Movement Disorders</i> , 1994 , 9, 76-83	7	526
138	The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. <i>Movement Disorders</i> , 2010 , 25, 704-9	7	266
137	Growth control of the eukaryote cell: a systems biology study in yeast. <i>Journal of Biology</i> , 2007 , 6, 4		208
136	International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. <i>Neurology</i> , 2009 , 73, 1584-91	6.5	186
135	Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. <i>Movement Disorders</i> , 2008 , 23, 1130-6	7	170
134	The non-motor symptom complex of Parkinson's disease: a comprehensive assessment is essential. Current Neurology and Neuroscience Reports, 2005 , 5, 275-83	6.6	161
133	Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. <i>Movement Disorders</i> , 2008 , 23, 1353-60	7	158
132	Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 840-4	5.5	156
131	A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004 , 75, 388-95	5.5	150
130	Burden, perceived health status, and mood among caregivers of Parkinson's disease patients. <i>Movement Disorders</i> , 2008 , 23, 1673-80	7	136
129	King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. <i>Movement Disorders</i> , 2015 , 30, 1623-31	7	131
128	Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 50-4	3.6	124
127	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1133-44	3.6	113
126	Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). <i>Journal of Neurology</i> , 2013 , 260, 228-36	5.5	113
125	Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's diseaseClinical practice recommendations. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1023-30	3.6	96
124	The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study. <i>Journal of the Neurological Sciences</i> , 2016 , 368, 150-4	3.2	96

(2014-2015)

123	The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 287-91	3.6	72
122	Pallidal stimulation relieves myoclonus-dystonia syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005 , 76, 989-91	5.5	70
121	The SCOPA-Motor Scale for assessment of Parkinson's disease is a consistent and valid measure. Journal of Clinical Epidemiology, 2005 , 58, 674-9	5.7	67
120	Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease. <i>European Journal of Neurology</i> , 2012 , 19, 105-13	6	66
119	Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. <i>European Journal of Neurology</i> , 2015 , 22, 37-43	6	63
118	Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 70-5	7	58
117	Global versus factor-related impression of severity in Parkinson's disease: a new clinimetric index (CISI-PD). <i>Movement Disorders</i> , 2006 , 21, 208-14	7	58
116	A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. <i>European Journal of Neurology</i> , 2016 , 23, 1255-0	6 ⁶	58
115	Psychometric attributes of the Hospital Anxiety and Depression Scale in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 519-25	7	56
114	Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson's disease heritability. <i>Npj Parkinson Disease</i> , 2019 , 5, 6	9.7	51
113	Non-motor symptoms burden in treated and untreated early Parkinson's disease patients: argument for non-motor subtypes. <i>European Journal of Neurology</i> , 2015 , 22, 1145-50	6	51
112	Independent validation of the scales for outcomes in Parkinson's disease-autonomic (SCOPA-AUT). <i>European Journal of Neurology</i> , 2010 , 17, 194-201	6	48
111	Mitochondria function associated genes contribute to Parkinson's Disease risk and later age at onset. <i>Npj Parkinsonp</i> s <i>Disease</i> , 2019 , 5, 8	9.7	47
110	Dementia associated with Parkinson's disease: applying the Movement Disorder Society Task Force criteria. <i>Parkinsonism and Related Disorders</i> , 2011 , 17, 621-4	3.6	47
109	The Clinical Impression of Severity Index for Parkinson's Disease: international validation study. <i>Movement Disorders</i> , 2009 , 24, 211-7	7	47
108	Pain in Parkinson's disease: facts and uncertainties. <i>European Journal of Neurology</i> , 2018 , 25, 917-e69	6	46
107	COPPADIS-2015 (COhort of Patients with PArkinson's Disease in Spain, 2015), a globalclinical evaluations, serum biomarkers, genetic studies and neuroimagingprospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. <i>BMC Neurology</i> , 2016 , 16, 26	3.1	46
106	Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: an international multicenter study. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1231-5	3.6	46

105	Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 151-157	3.6	39
104	Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 536-544	2.2	38
103	Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. <i>European Journal of Neurology</i> , 2014 , 21, 519-24	6	35
102	The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 889-93	3.6	34
101	Advanced Parkinson's disease: clinical characteristics and treatment. Part II. Neurologa, 2013, 28, 558-8.	31.4	31
100	Clinical assessment of nocturnal disability in Parkinson's disease: the Parkinson's Disease Sleep Scale. <i>Neurology</i> , 2004 , 63, S17-20	6.5	31
99	Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. <i>Parkinsonism and Related Disorders</i> , 2018 , 52, 83-89	3.6	28
98	Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. <i>Movement Disorders</i> , 2020 , 35, 774-780	7	27
97	Night-time sleep in Parkinson's disease - the potential use of Parkinson's KinetiGraph: a prospective comparative study. <i>European Journal of Neurology</i> , 2016 , 23, 1275-88	6	27
96	Rasch analysis of the hospital anxiety and depression scale in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 526-32	7	26
95	Intermediate scale for assessment of Parkinson's disease. Characteristics and structure. <i>Parkinsonism and Related Disorders</i> , 1995 , 1, 97-102	3.6	24
94	Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2020 , 27, 1210-1223	6	22
93	Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis. <i>PLoS ONE</i> , 2015 , 10, e0145310	3.7	22
92	COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation. <i>European Journal of Neurology</i> , 2019 , 26, 1399-1407	6	21
91	Dopaminergic agonists in Parkinson's disease. <i>Neurolog</i> ā , 2014 , 29, 230-41	1.4	20
90	Analysis of four scales for global severity evaluation in Parkinson's disease. <i>Npj Parkinson</i> s <i>Disease</i> , 2016 , 2, 16007	9.7	20
89	Drug-induced parkinsonism: a growing list. <i>Movement Disorders</i> , 1993 , 8, 125	7	19
88	Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson's disease. <i>Journal of Medical Genetics</i> , 2020 , 57, 331-338	5.8	19

(2018-2019)

87	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , 2019 , 34, 1851-	1863	18	
86	Atypical parkinsonism with apraxia and supranuclear gaze abnormalities in type 1 Gaucher disease. Expanding the spectrum: case report and literature review. <i>Movement Disorders</i> , 2010 , 25, 1506-9	7	18	
85	Implantation of the human embryo: research lines and models. From the implantation research network 'Fruitful'. <i>Gynecologic and Obstetric Investigation</i> , 2006 , 62, 206-16	2.5	18	
84	Botulinum toxin therapy of migraine and tension-type headache: comparing different botulinum toxin preparations. <i>European Journal of Neurology</i> , 2006 , 13 Suppl 1, 51-4	6	18	
83	Antiphospholipid antibodies in migraine. <i>Headache</i> , 1991 , 31, 666-8	4.2	18	
82	Satisfaction with Life Scale (SLS-6): First validation study in Parkinson's disease population. <i>Parkinsonism and Related Disorders</i> , 2016 , 25, 52-7	3.6	16	
81	Acute paroxysmal dystonia induced by fluoxetine. Movement Disorders, 2001, 16, 767-9	7	16	
80	Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2017 , 40, 103-107	1.4	15	
79	Remote Monitoring of Treatment Response in Parkinson's Disease: The Habit of Typing on a Computer. <i>Movement Disorders</i> , 2019 , 34, 1488-1495	7	15	
78	Influencing factors when living with Parkinson's disease: A cross-sectional study. <i>Journal of Clinical Nursing</i> , 2019 , 28, 3168-3176	3.2	15	
77	Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study. <i>Journal of Neurology</i> , 2011 , 258, 1055-7	5.5	15	
76	Sonography for diagnosis of Parkinson disease-from theory to practice: a study on 300 participants. <i>Journal of Ultrasound in Medicine</i> , 2014 , 33, 2069-74	2.9	14	
<i>75</i>	LRP10 in Esynucleinopathies. Lancet Neurology, The, 2018 , 17, 1032	24.1	14	
74	First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire. <i>European Journal of Neurology</i> , 2018 , 25, 1255-1261	6	14	
73	Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 742-8	3.6	13	
7²	Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience. <i>Toxins</i> , 2018 , 10,	4.9	13	
71	Botulism with sensory symptoms: a second case. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991 , 54, 844-5	5.5	13	
70	Minimal Clinically Important Difference for UPDRS-III in Daily Practice. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 448-450	2.2	12	

69	Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants. <i>Parkinsonism and Related Disorders</i> , 2018 , 49, 100-103	3.6	11
68	Lack of validation of variants associated with cervical dystonia risk: a GWAS replication study. <i>Movement Disorders</i> , 2014 , 29, 1825-8	7	11
67	The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validation project. <i>Parkinson</i> Disease, 2011 , 2011, 125271	2.6	11
66	Stroke and pulmonary thromboembolism after a long flight. <i>European Journal of Neurology</i> , 2005 , 12, 732-4	6	11
65	Sleep Problems Are Related to a Worse Quality of Life and a Greater Non-Motor Symptoms Burden in Parkinson's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021 , 34, 642-658	3.8	11
64	Late onset Huntington's disease with 29 CAG repeat expansion. <i>Journal of the Neurological Sciences</i> , 2016 , 363, 114-5	3.2	11
63	Impulse control and related behaviors in Parkinson's disease with dementia. <i>European Journal of Neurology</i> , 2020 , 27, 944-950	6	10
62	Antidepressants in Parkinson's disease. Recommendations by the movement disorder study group of the Neurological Association of Madrid. <i>Neurologi</i> a, 2016 , 33, 395-395	1.4	10
61	Should the SCOPA-COG be modified? A Rasch analysis perspective. <i>European Journal of Neurology</i> , 2010 , 17, 202-7	6	10
60	Botulinum toxin in a task-specific oromandibular dystonia in a bingo caller. <i>Journal of Neurology</i> , 2008 , 255, 942-3	5.5	10
59	Dyskinesia-hyperpyrexia syndrome under continuous dopaminergic stimulation. <i>Parkinsonism and Related Disorders</i> , 2017 , 36, 103-104	3.6	9
58	Living with chronic illness scale: international validation of a new self-report measure in Parkinson's disease. <i>Npj Parkinsonp</i> s <i>Disease</i> , 2016 , 2, 16022	9.7	9
57	High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2019 , 126, 1599-1608	4.3	9
56	Autonomous stump movements responsive to gabapentin. <i>Journal of Neurology</i> , 2004 , 251, 346-7	5.5	9
55	Impact of SAfinamide on Depressive Symptoms in Parkinson's Disease Patients (SADness-PD Study): A Multicenter Retrospective Study. <i>Brain Sciences</i> , 2021 , 11,	3.4	9
54	BDNF Val66Met polymorphism in primary adult-onset dystonia: a case-control study and meta-analysis. <i>Movement Disorders</i> , 2014 , 29, 1083-6	7	8
53	Creativity related to dopaminergic treatment: A multicenter study. <i>Parkinsonism and Related Disorders</i> , 2019 , 63, 169-173	3.6	7
52	Remote control of apomorphine infusion rate in Parkinson's disease: Real-time dose variations according to the patients' motor state. A proof of concept. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 996-8	3.6	7

(2021-2018)

51	Phenomenology and disease progression of chorea-acanthocytosis patients in Spain. <i>Parkinsonism and Related Disorders</i> , 2018 , 49, 17-21	3.6	7
50	Transcranial sonography in atypical parkinsonism: How reliable is it in real clinical practice? A multicentre comprehensive study. <i>Parkinsonism and Related Disorders</i> , 2019 , 68, 40-45	3.6	7
49	Sexual Dysfunction in Early-Onset Parkinson's Disease: A Cross-Sectional, Multicenter Study. Journal of Parkinsons Disease, 2020 , 10, 1621-1629	5.3	7
48	Clinical management of patients with advanced Parkinson's disease treated with continuous intestinal infusion of levodopa/carbidopa. <i>Neurodegenerative Disease Management</i> , 2016 , 6, 187-202	2.8	7
47	Art and dystonia. Journal of the Neurological Sciences, 2015, 356, 49-54	3.2	6
46	Self-Assessment of Disability in Parkinson's Disease: The MDS-UPDRS Part II Versus Clinician-Based Ratings. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 529-535	2.2	6
45	Familial focal dystonia. European Neurology, 2002 , 48, 232-4	2.1	6
44	Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life. <i>Parkinsongs Disease</i> , 2021 , 2021, 8871549	2.6	6
43	SURINPARK: Safinamide for Urinary Symptoms in Parkinson's Disease. <i>Brain Sciences</i> , 2021 , 11,	3.4	6
42	Nonmotor disorders and their correlation with dopamine: can they be treated by currently available methods?. <i>Neurologist</i> , 2011 , 17, S9-17	1.6	5
41	Humoral response to the human heat shock 60 kDa protein in myasthenia gravis. <i>Journal of the Neurological Sciences</i> , 1996 , 135, 182-3	3.2	5
40	Substantia Nigra Echogenicity Predicts Response to Drug Withdrawal in Suspected Drug-Induced Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 268-274	2.2	5
39	Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 25-32	2.2	5
38	The Parkinson's Disease Sleep Scale-2 (PDSS-2): Validation of the Spanish Version and Its Relationship With a Roommate-Based Version. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 294-301	2.2	4
37	Discussing sexuality with Parkinson's disease patients: a multinational survey among neurologists. Journal of Neural Transmission, 2019 , 126, 1273-1280	4.3	4
36	Developmental venous anomaly of the pons. <i>Neurology</i> , 2001 , 57, 744	6.5	4
35	Carbidopa-induced eosinophilic fasciitis: A review. <i>Neurology India</i> , 2016 , 64, 157-9	0.7	4
34	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	4

33	Predictors of clinically significant quality of life impairment in Parkinson's disease <i>Npj Parkinsonp</i> s <i>Disease</i> , 2021 , 7, 118	9.7	4
32	Ancient representation of Meige's syndrome in the Moche culture in the pre-Columbian Peru. <i>Movement Disorders</i> , 2010 , 25, 405-6	7	3
31	Sudden headache associated with unilateral asterixis. <i>Headache</i> , 1988 , 28, 352-3	4.2	3
30	Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease <i>Journal of the Neurological Sciences</i> , 2022 , 434, 120148	3.2	3
29	A genetic analysis of a Spanish population with early onset Parkinson's disease. <i>PLoS ONE</i> , 2020 , 15, e0.	23,8098	3 3
28	Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression. <i>Journal of the Neurological Sciences</i> , 2020 , 418, 117109	3.2	3
27	Simultaneous acute presentation of generalized chorea and subacute combined degeneration secondary to vitamin B12 deficiency. <i>Parkinsonism and Related Disorders</i> , 2018 , 55, 2-4	3.6	3
26	Spanish expert consensus on the use of safinamide in Parkinson's disease. <i>Neurolog</i> ā, 2018 , 36, 666-666	5 1.4	3
25	Does normal substantia nigra echogenicity make a difference in Parkinson's disease diagnosis? A real clinical practice follow-up study. <i>Journal of Neurology</i> , 2018 , 265, 2363-2369	5.5	2
24	Cervical dystonia and Constantin Brancusi. <i>Movement Disorders</i> , 2009 , 24, 1849-50	7	2
23	Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. <i>Journal of Parkinsonps Disease</i> , 2021 ,	5.3	2
22	Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort. <i>Scientific Reports</i> , 2020 , 10, 16893	4.9	2
21	Falls Predict Acute Hospitalization in Parkinson's Disease. Journal of Parkinson Disease, 2021,	5.3	2
20	Impulse Control Disorders in Parkinson's Disease: Has COVID-19 Related Lockdown Been a Trigger?. Movement Disorders Clinical Practice, 2021 , 8, 940-943	2.2	2
19	Predictors of Loss of Functional Independence in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group. <i>Diagnostics</i> , 2021 , 11,	3.8	2
18	Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome <i>Nature Communications</i> , 2021 , 12, 7342	17.4	2
17	Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease. <i>BMC Neurology</i> , 2021 , 21, 477	3.1	2
16	Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson Disease Patients: A 2-Year Follow-Up Study. <i>Diagnostics</i> , 2022 , 12, 1147	3.8	2

LIST OF PUBLICATIONS

15	Alterations in dexterity and manual function in patients with focal hand dystonia. <i>Neurolog</i> a , 2020 ,	1.4	1
14	SEIdrome de leucoencefalopatEl posterior en relaciEl con angiopatEl amiloide. <i>Neurolog</i> El, 2010 , 25, 391-393	1.4	1
13	Prevalence of Advanced Parkinson's Disease in Patients Treated in the Hospitals of the Spanish National Healthcare System: The PARADISE Study <i>Brain Sciences</i> , 2021 , 11,	3.4	1
12	The genetic architecture of Parkinson disease in Spain: characterizing population-specific risk, differential haplotype structures, and providing etiologic insight		1
11	Mutational spectrum of GNAL, THAP1 and TOR1A genes in isolated dystonia: study in a population from Spain and systematic literature review. <i>European Journal of Neurology</i> , 2021 , 28, 1188-1197	6	1
10	The Impact of Anxiety and Upper Limb Disability on Participation Levels in People With Dystonia: An Observational Cross-Sectional Case-Control Study. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2021 , 100, 77-81	2.6	O
9	Spanish expert consensus on the use of safinamide in Parkinson's disease. <i>Neurolog</i> a (English Edition), 2021 , 36, 666-672	0.4	О
8	Cervical Dystonia in Modigliani's Paintings: The Clue Was the Sensory Trick. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 346-347	2.2	
7	Perioperative Management of Parkinson's Disease. Cirugā Espaōla (English Edition), 2011 , 89, 427-431	0.1	
6	Cut off selection in anti-acetylcholine receptor antibody determination. <i>Journal of Neurology,</i> Neurosurgery and Psychiatry, 1994 , 57, 1018	5.5	
5	Multicentre, randomised, single-blind, parallel group trial to compare the effectiveness of a Holter for Parkinson's symptoms against other clinical monitoring methods: study protocol. <i>BMJ Open</i> , 2021 , 11, e045272	3	
4	Eye-of-the-Tiger Sign with an Unexpected Pathological Diagnosis <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 98-103	2.2	
3	Reply to: "Reply to Late onset Huntington's disease with 29 CAG repeat expansion" JNS-D-16-00732. <i>Journal of the Neurological Sciences</i> , 2016 , 369, 390	3.2	
2	Management of Parkinson's disease and other movement disorders in woman of childbearing age: Part 1. <i>Neurolog</i> ā , 2021 , 36, 149-158	1.4	
1	Management of Parkinson's disease and other movement disorders in women of childbearing age: Part 2. <i>Neurolog</i> ā , 2021 , 36, 159-168	1.4	